Share：
Share this content in WeChat
X
[Chinese][PDF]4741
• Clinical Article •
Study on the correlation between multi-parameter MRI and pathology in the tumor body and peritumoral area of breast cancer
ZHOU Shihao  WANG Xuejia  CHENG Sijia  ZHOU Fengmei  HAN Dongming 

Cite this article as: ZHOU S H, WANG X J, CHENG S J, et al. Study on the correlation between multi-parameter MRI and pathology in the tumor body and peritumoral area of breast cancer[J]. Chin J Magn Reson Imaging, 2023, 14(3): 72-80. DOI:10.12015/issn.1674-8034.2023.03.013.


[Abstract] Objective To explore the differential diagnosis value of amino proton transfer (APT) imaging and diffusion kurtosis imaging (DKI) alone and in combination in the differential diagnosis of benign and malignant breast lesions, and analyze the correlation between peritumoral parameters and pathological factors of breast cancer.Materials and Methods A retrospective analysis was performed on 56 case data of patients with breast lesions. Dynamic contrast-enhanced (DCE) MRI, diffusion weighted imaging (DWI), APT and DKI scans were performed before operation, and the magnetization transfer ratio asymmetry (MTRasym) and mean kurtosis (MK), mean diffusivity (MD), and the apparent diffusion coefficient (ADC) value and the Breast Imaging Reporting and Data System (BI-RADS) classification of the lesion were recorded. The differences in parameters between the benign and malignant groups were compared and analyzed, the combined diagnostic model was established by logistic regression analysis, and the receiver operating characteristic (ROC) curve was used to analyze the diagnostic efficiency of different parameters and the combined model for benign and malignant breast lesions. The ratios of tumor peritumor to tumor body MTRasymp/t, MKp/t, MDp/t, peritumoral and contralateral normal glands MTRasymp/n, MKp/n, MDp/n of each parameter were calculated respectively, and compared differences among groups of different pathological factors.Results The MK value of the malignant group was higher than that of the benign group, and the ADC, MD and MTRasym values were lower than those of the benign group, and the differences were statistically significant (P＜0.05). The area under the curves (AUCs) of ADC, MK, MD, MTRasym, DCE, DCE+ADC, DCE+ADC+DKI+APT in diagnosing benign and malignant breast lesions were 0.819, 0.914, 0.895, 0.752, 0.744, 0.886, 0.985. The AUCs of MK and MD were significantly higher than that of DCE, the AUC of MK was significantly higher than that of MTRasym, the AUC of DCE+ADC+DKI+APT were significantly higher than that of other parameters (P＜0.05). The results of peritumoral parameter analysis showed that MKp/t has weak negative correlation with HER-2 state (r=-0.365, P=0.043), MKp/t has moderate negative correlation with Ki-67 expression (r=-0.404, P=0.024), MDp/t has moderate positive correlation with Ki-67 expression (r=0.420, P=0.019), MKp/n has weak positive correlation with lymphatic vascular invasion (LVI) (r=0.382, P=0.034), MDp/n has weak negative correlation with LVI (r=-0.373, P=0.039), MKp/n has weak positive correlation with histological grade (r=0.376, P=0.043).Conclusions Both APT and DKI showed high diagnostic efficiency in differentiating benign and malignant breast lesions, and the diagnostic efficiency of multi-parameter combined application was significantly improved. DKI parameters can indicate the impact of breast cancer with different pathological factors on the peritumoral area. Therefore, APT and DKI technology can provide assistance for the diagnosis of breast cancer, the assessment of tumor invasiveness and the formulation of treatment plan.
[Keywords] breast neoplasms；amino proton transfer imaging；diffusion kurtosis imaging；peritumoral area；pathological factors；magnetic resonance imaging

ZHOU Shihao   WANG Xuejia   CHENG Sijia   ZHOU Fengmei   HAN Dongming*  

Department of MRI, the First Affiliated Hospital of Xinxiang Medical University, Xinxiang 453100, China

Corresponding author: Han DM, E-mail: 625492590@qq.com

Conflicts of interest   None.

ACKNOWLEDGMENTS Medical Science and Technological Project of Henan Province (No. 2018020367); Medical Research Development Fund Project of Beijing Kangmeng Charity Foundation (No. B21145AN).
Received  2022-10-21
Accepted  2023-02-25
DOI: 10.12015/issn.1674-8034.2023.03.013
Cite this article as: ZHOU S H, WANG X J, CHENG S J, et al. Study on the correlation between multi-parameter MRI and pathology in the tumor body and peritumoral area of breast cancer[J]. Chin J Magn Reson Imaging, 2023, 14(3): 72-80. DOI:10.12015/issn.1674-8034.2023.03.013.

[1]
SUNG H, FERLAY J, SIEGEL R L, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries[J]. CA Cancer J Clin, 2021, 71(3): 209-249. DOI: 10.3322/caac.21660.
[2]
WAKS A G, WINER E P. Breast cancer treatment: a review[J]. JAMA, 2019, 321(3): 288-300. DOI: 10.1001/jama.2018.19323.
[3]
HAYNES B, SARMA A, NANGIA-MAKKER P, et al. Breast cancer complexity: implications of intratumoral heterogeneity in clinical management[J]. Cancer Metastasis Rev, 2017, 36(3): 547-555. DOI: 10.1007/s10555-017-9684-y.
[4]
BARZGAR BAROUGH N, SAJJADIAN F, JALILZADEH N, et al. Understanding breast cancer heterogeneity through non-genetic heterogeneity[J]. Breast Cancer, 2021, 28(4): 777-791. DOI: 10.1007/s12282-021-01237-w.
[5]
OSHIRO C, YAMASAKI M, NODA Y, et al. Comparative evaluation of nuclear and histological grades as prognostic factors for invasive breast cancer[J]. Breast Cancer, 2020, 27(5): 947-953. DOI: 10.1007/s12282-020-01093-0.
[6]
KIM J, DE SAMPAIO P C, LUNDY D M, et al. Heterogeneous perivascular cell coverage affects breast cancer metastasis and response to chemotherapy[J/OL]. JCI Insight, 2016, 1(21): e90733 [2022-10-26]. https://insight.jci.org/articles/view/90733. DOI: 10.1172/jci.insight.90733.
[7]
POLYAK K, KALLURI R. The role of the microenvironment in mammary gland development and cancer[J/OL]. Cold Spring Harb Perspect Biol, 2010, 2(11): a003244 [2022-10-26]. https://doi.org/10.1101/cshperspect.a003244. DOI: 10.1101/cshperspect.a003244.
[8]
WANG D M, ZHU K, TIAN J W, et al. Clinicopathological and ultrasonic features of triple-negative breast cancers: a comparison with hormone receptor-positive/human epidermal growth factor receptor-2-negative breast cancers[J]. Ultrasound Med Biol, 2018, 44(5): 1124-1132. DOI: 10.1016/j.ultrasmedbio.2018.01.013.
[9]
SUMKIN J H, BERG W A, CARTER G J, et al. Diagnostic performance of MRI, molecular breast imaging, and contrast-enhanced mammography in women with newly diagnosed breast cancer[J]. Radiology, 2019, 293(3): 531-540. DOI: 10.1148/radiol.2019190887.
[10]
JENSEN J H, HELPERN J A, RAMANI A, et al. Diffusional kurtosis imaging: the quantification of non-Gaussian water diffusion by means of magnetic resonance imaging[J]. Magn Reson Med, 2005, 53(6): 1432-1440. DOI: 10.1002/mrm.20508.
[11]
ZHOU J Y, PAYEN J F, WILSON D A, et al. Using the amide proton signals of intracellular proteins and peptides to detect pH effects in MRI[J]. Nat Med, 2003, 9(8): 1085-1090. DOI: 10.1038/nm907.
[12]
MENG N, WANG X J, SUN J, et al. A comparative study of the value of amide proton transfer-weighted imaging and diffusion kurtosis imaging in the diagnosis and evaluation of breast cancer[J]. Eur Radiol, 2021, 31(3): 1707-1717. DOI: 10.1007/s00330-020-07169-x.
[13]
KANG H S, KIM J Y, KIM J J, et al. Diffusion kurtosis MR imaging of invasive breast cancer: correlations with prognostic factors and molecular subtypes[J]. J Magn Reson Imaging, 2022, 56(1): 110-120. DOI: 10.1002/jmri.27999.
[14]
ZHANG S, RAUCH G M, ADRADA B E, et al. Assessment of early response to neoadjuvant systemic therapy in triple-negative breast cancer using amide proton transfer-weighted chemical exchange saturation transfer MRI: a pilot study[J/OL]. Radiol Imaging Cancer, 2021, 3(5): e200155 [2023-01-03]. https://doi.org/10.1148/rycan.2021200155. DOI: 10.1148/rycan.2021200155.
[15]
LI X S, FENG R, WANG D, et al. The comparison of the value of mono-exponential mode and diffusion kurtosis imaging mode in predicting the response to neoadjuvant chemotherapy for locally advanced breast carcinoma using diffusion-weighted imaging[J]. Chin J Radiol, 2019, 53(1): 26-32. DOI: 10.3760/cma.j.issn.1005-1201.2019.01.007.
[16]
PARK N J, JEONG J Y, PARK J Y, et al. Peritumoral edema in breast cancer at preoperative MRI: an interpretative study with histopathological review toward understanding tumor microenvironment[J/OL]. Sci Rep, 2021, 11(1): 12992 [2023-01-03]. https://doi.org/10.1038/s41598-021-92283-z. DOI: 10.1038/s41598-021-92283-z.
[17]
DA LUZ F A C, COSTA MARINHO E DA, NASCIMENTO C P, et al. Prognosis value of lymphovascular invasion in patients with invasive ductal breast carcinoma according to lymph node metastasis status[J/OL]. Ecancermedicalscience, 2022, 16: 1364 [2023-01-26]. https://doi.org/10.3332/ecancer.2022.1364. DOI: 10.3332/ecancer.2022.1364.
[18]
BRAMAN N M, ETESAMI M, PRASANNA P, et al. Intratumoral and peritumoral radiomics for the pretreatment prediction of pathological complete response to neoadjuvant chemotherapy based on breast DCE-MRI[J/OL]. Breast Cancer Res, 2017, 19(1): 57 [2023-01-03]. https://doi.org/10.1186/s13058-017-0846-1. DOI: 10.1186/s13058-017-0846-1.
[19]
MORI N, MUGIKURA S, TAKASAWA C, et al. Peritumoral apparent diffusion coefficients for prediction of lymphovascular invasion in clinically node-negative invasive breast cancer[J]. Eur Radiol, 2016, 26(2): 331-339. DOI: 10.1007/s00330-015-3847-4.
[20]
Breast Cancer Professional Committee of China Anti-Cancer Association. Guidelines and norms for diagnosis and treatment of breast cancer of China Anti-Cancer Association (2021 edition)[J]. China Oncol, 2021, 31(10): 954-1040. DOI: 10.19401/j.cnki.1007-3639.2021.10.013.
[21]
Compilation group of guidelines for immunohistochemical detection of progesterone receptor in breast cancer females. Guidelines for immunohistochemical detection of estrogen and progesterone receptors in breast cancer[J]. Chin J Pathol, 2015, 44(4): 237-239. DOI: 10.3760/cma.j.issn.0529-5807.2015.04.005.
[22]
Compilation group of guidelines for HER2 detection in breast cancer. Guideline for HER2 detection in breast cancer, the 2019 version[J]. Chin J Pathol, 2019, 48(3): 169-175. DOI: 10.3760/cma.j.issn.0529-5807.2019.03.001.
[23]
GOLDHIRSCH A, WINER E P, COATES A S, et al. Personalizing the treatment of women with early breast cancer: highlights of the St Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2013[J]. Ann Oncol, 2013, 24(9): 2206-2223. DOI: 10.1093/annonc/mdt303.
[24]
KARIRI Y A, ALESKANDARANY M A, JOSEPH C, et al. Molecular complexity of lymphovascular invasion: the role of cell migration in breast cancer as a prototype[J]. Pathobiology, 2020, 87(4): 218-231. DOI: 10.1159/000508337.
[25]
MEI F, LIU J Y, XUE W C. Histological grading of invasive breast carcinoma: Nottingham histological grading system[J]. Chin J Pathol, 2019, 48(8): 659-664. DOI: 10.3760/cma.j.issn.0529-5807.2019.08.019.
[26]
JENSEN J H, HELPERN J A. MRI quantification of non-Gaussian water diffusion by kurtosis analysis[J]. NMR Biomed, 2010, 23(7): 698-710. DOI: 10.1002/nbm.1518.
[27]
MARZI S, MINOSSE S, VIDIRI A, et al. Diffusional kurtosis imaging in head and neck cancer: on the use of trace-weighted images to estimate indices of non-Gaussian water diffusion[J]. Med Phys, 2018, 45(12): 5411-5419. DOI: 10.1002/mp.13238.
[28]
LI T, HONG Y, KONG D X, et al. Histogram analysis of diffusion kurtosis imaging based on whole-volume images of breast lesions[J]. J Magn Reson Imaging, 2020, 51(2): 627-634. DOI: 10.1002/jmri.26884.
[29]
LIU W, WEI C G, BAI J Y, et al. Histogram analysis of diffusion kurtosis imaging in the differentiation of malignant from benign breast lesions[J]. Eur J Radiol, 2019, 117: 156-163. DOI: 10.1016/j.ejrad.2019.06.008.
[30]
GU H Y, CUI W J, LUO S, et al. Diagnostic performance of diffusion kurtosis imaging for benign and malignant breast lesions: a systematic review and meta-analysis[J/OL]. Appl Bionics Biomech, 2022, 2022: 2042736 [2022-10-26]. https://doi.org/10.1155/2022/2042736. DOI: 10.1155/2022/2042736.
[31]
MENG N, WANG X J, SUN J, et al. Comparative study of amide proton transfer-weighted imaging and intravoxel incoherent motion imaging in breast cancer diagnosis and evaluation[J]. J Magn Reson Imaging, 2020, 52(4): 1175-1186. DOI: 10.1002/jmri.27190.
[32]
WANG R H, ZHANG Y, CHENG J L, et al. The value of three-dimensional amide proton transfer-weighted imaging and its combination with diffusion weighted imaging in diagnosing breast benign and malignant lesions[J]. Chin J Radiol, 2022, 56(3): 266-272. DOI: 10.3760/cma.j.cn112149-20210304-00187.
[33]
LIU Z, WEN J, WANG M, et al. Breast amide proton transfer imaging at 3 T: diagnostic performance and association with pathologic characteristics[J]. J Magn Reson Imaging, 2023, 57(3): 824-833. DOI: 10.1002/jmri.28335.
[34]
KAMITANI T, SAGIYAMA K, TOGAO O, et al. Amide proton transfer (APT) imaging of parotid tumors: differentiation of malignant and benign tumors[J/OL]. Eur J Radiol, 2020, 129: 109047 [2022-10-26]. https://doi.org/10.1016/j.ejrad.2020.109047. DOI: 10.1016/j.ejrad.2020.109047.
[35]
KULANTHAIVELU K, JABEEN S, SAINI J, et al. Amide proton transfer imaging for differentiation of tuberculomas from high-grade gliomas: preliminary experience[J]. Neuroradiol J, 2021, 34(5): 440-448. DOI: 10.1177/19714009211002766.
[36]
ZHANG N, KANG J Y, WANG H L, et al. Differentiation of fibroadenomas versus malignant breast tumors utilizing three-dimensional amide proton transfer weighted magnetic resonance imaging[J]. Clin Imaging, 2022, 81: 15-23. DOI: 10.1016/j.clinimag.2021.09.002.
[37]
DING G L, ZHANG Y Q, XING H Y, et al. Distribution of the different fibers in the fibroepithelial neoplasia of the breast[J]. Chin J Clin Exp Pathol, 2013, 29(11): 1184-1186. DOI: 10.13315/j.cnki.cjcep.2013.11.011.
[38]
RAY K J, SIMARD M A, LARKIN J R, et al. Tumor pH and protein concentration contribute to the signal of amide proton transfer magnetic resonance imaging[J]. Cancer Res, 2019, 79(7): 1343-1352. DOI: 10.1158/0008-5472.CAN-18-2168.
[39]
ZHOU J Y, HONG X H, ZHAO X N, et al. APT-weighted and NOE-weighted image contrasts in glioma with different RF saturation Powers based on magnetization transfer ratio asymmetry analyses[J]. Magn Reson Med, 2013, 70(2): 320-327. DOI: 10.1002/mrm.24784.
[40]
RAKHA E A, EL-SAYED M E, LEE A H S, et al. Prognostic significance of Nottingham histologic grade in invasive breast carcinoma[J]. J Clin Oncol, 2008, 26(19): 3153-3158. DOI: 10.1200/JCO.2007.15.5986.
[41]
CHOI B B. Dynamic contrast enhanced-MRI and diffusion-weighted image as predictors of lymphovascular invasion in node-negative invasive breast cancer[J/OL]. World J Surg Oncol, 2021, 19(1): 76 [2022-10-26]. https://doi.org/10.1186/s12957-021-02189-3. DOI: 10.1186/s12957-021-02189-3.
[42]
WANG L L, LI J F, LEI J Q, et al. The value of the signal intensity of peritumoral tissue on Gd-EOB-DTPA dynamic enhanced MRI in assessment of microvascular invasion and pathological grade of hepatocellular carcinoma[J/OL]. Medicine (Baltimore), 2021, 100(20): e25804 [2022-10-26]. https://doi.org/10.1097/MD.0000000000025804. DOI: 10.1097/MD.0000000000025804.
[43]
QIU J, DENG K X, WANG P, et al. Application of diffusion kurtosis imaging to the study of edema in solid and peritumoral areas of glioma[J]. Magn Reson Imaging, 2022, 86: 10-16. DOI: 10.1016/j.mri.2021.11.001.
[44]
GE T W, CUI J W. Research progress on mutual promotion mechanism between tumor and tumor inflammatory microenvironment[J]. Chin J Clin Lab Sci, 2017, 35(11): 832-835. DOI: 10.13602/j.cnki.jcls.2017.11.08.
[45]
ZHOU L, XIONG L. Correlations between different apparent diffusion coefficients and lymphatic invasion in the breast cancer[J]. Radiol Pract, 2019, 34(7): 788-791. DOI: 10.13609/j.cnki.1000-0313.2019.07.014.
[46]
CHUNG I, REICHELT M, SHAO L, et al. High cell-surface density of HER2 deforms cell membranes[J/OL]. Nat Commun, 2016, 7: 12742 [2022-10-26]. https://doi.org/10.1038/ncomms12742. DOI: 10.1038/ncomms12742.
[47]
HUANG Y, LIN Y, HU W, et al. Diffusion kurtosis at 3.0T as an in vivo imaging marker for breast cancer characterization: correlation with prognostic factors[J]. J Magn Reson Imaging, 2019, 49(3): 845-856. DOI: 10.1002/jmri.26249.
[48]
ALESKANDARANY M A, GREEN A R, ASHANKYTY I, et al. Impact of intratumoural heterogeneity on the assessment of Ki67 expression in breast cancer[J]. Breast Cancer Res Treat, 2016, 158(2): 287-295. DOI: 10.1007/s10549-016-3893-x.
[49]
DAVEY M G, HYNES S O, KERIN M J, et al. Ki-67 as a prognostic biomarker in invasive breast cancer[J/OL]. Cancers (Basel), 2021, 13(17): 4455 [2022-10-26]. https://doi.org/10.3390/cancers13174455. DOI: 10.3390/cancers13174455.
[50]
TANG W X, SHENG M H, GONG S C, et al. Diagnostic value of T2WI relative signal intensity ratio combined with peritumoral edema in benign and malignant breast lesions[J]. J Clin Radiol, 2020, 39(12): 2411-2414. DOI: 10.13437/j.cnki.jcr.2020.12.013.
[51]
DIAS A S, ALMEIDA C R, HELGUERO L A, et al. Metabolic crosstalk in the breast cancer microenvironment[J]. Eur J Cancer, 2019, 121: 154-171. DOI: 10.1016/j.ejca.2019.09.002.

PREV Study on the value of mDixon-Quant technique in the diagnosis and prognosis evaluation of invasive ductal breast cancer
NEXT Prediction of axillary lymph node metastasis in breast cancer based on intra-tumoral and peri-tumoral MRI radiomics nomogram
  


LINK


Tel & Fax: +8610-67113815    E-mail: editor@cjmri.cn